Biogen to start shipping new Alzheimer's drug in two weeks

More than 900 clinics and hospitals around the US are ready to administer Biogen's recently-approved drug Aduhelm to Alzheimer's patients.


Significantly more infusion centers than expected are ready to give patients suffering from Alzheimer's disease Biogen's new medication Aduhelm, according to Fiercepharma.

900 infusion centers will be poised to administer this medication when Biogen starts shipping it in two weeks' time. In April, the estimated number of infusion centers was 600. In total, the US company estimates that 1,200 clinics around the US will be able to administer Aduhelm.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs